More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Drop in Restasis Revenue Creates Hurdle for Would-be Competitors
Author: Peter Downs
The manufacturer’s revenue from Restasis (cyclosporine ophthalmic emulsion 0.05%) tumbled over the last three years, falling 20 percent to $1.2 billion in 2020 from $1.5 billion in 2017. No generics entered the market to take sales away from Restasis, and Xiidra sales were steady, so what’s causing the incredible shrinkage in Restasis revenue? The answer seems to be a combination of fewer prescriptions and deeper discounts. Although Allergan and AbbVie reported falling revenues, Symphony Heal...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.